Last updated on April 2019

Tacrolimus Monotherapy for Idiopathic Membranous Nephropathy (IMN)


Brief description of study

The trial is a random, open, control and monocentric trial. Mainly to assess the urine protein remission rate of tacrolimus (TAC) monotherapy for idiopathic membranous nephropathy (IMN). Assuming that the urine protein remission rate of 48-week TAC for monotherapy of IMN is not lower than that in treatment group of TAC combined with glucocorticoid, attempt on de-hormonal therapy in the future IMN therapy can be attempted on the basis of the trial results.

Clinical Study Identifier: NCT03549663

Find a site near you

Start Over